Immunological relatedness of the protective mechanisms against tuberculosis and cancer

European Journal of Clinical Investigation

Volumn 28, Issue 1, 1998, Pages 1-12

  Cocito, C ^a,b   Maes, H ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cancer prophylaxis; Cytokines and cancer; Immune alterations by neoplasia; Immunotherapy of tumours; Mycobacteria; Mycobacterial antigens

Indexed keywords

A 60; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER PREVENTION; CELL LINE; CELL PROLIFERATION; HUMAN; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; TUMOR CELL;

ANIMALS; BCG VACCINE; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUBERCULOSIS;

EID: 0031930374     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00248.x     Document Type: Review

References (98)

1. Colditz GA, Brewer TF, Berkey DS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Journal of the American Medical Association, 1994; 271: 698-702.
2. Fine PEM. Bacille Calmette-Guérin vaccines: a rough guide. Clinical Infectious Diseases, 1995; 20: 11-14.
3. Roche PW, Triccas JA, Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends in Microbiology, 1995; 3: 397-401.
4. Hersh EM, Gutterman JU, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Annual Review of Medicine, 1977; 28: 489-515.
5. Baldwin RW, Pimm MV. BCG in tumour immunotherapy. Advances in Cancer Research, 1978; 28: 91-147.
6. Milas L, Scott MT. Antitumour activity of Corynebacterium parvum. Advances in Cancer Research, 1978; 26: 257-306.
7. Lotze MT, Finn OJ. Cellular Immunity and Immunotherapy of Cancer. New York: Wiley-Liss, 1990.
8. Oldam RK. Principles of Cancer Biotherapy. New York: M. Dekker, 1991.
9. De Vita VT, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer. Philadelphia: Lippincott, 1991.
10. Lamoureux G, Turcotte R, Portellance V, eds. BCG in Cancer Immunotherapy. New York: Grune & Stratton, 1976.
11. Youmans GP. Pathogenesis of tuberculosis. In: Youmans GP, ed. Tuberculosis. Philadelphia: WB Saunders, 1979: 317-326.
12. Youmans GP. Tuberculosis. In: Youmans GP, Paterson PY, Sommers HM, eds. The Biological and Clinical Basis of Infectious Diseases. Philadelphia: WB Saunders, 1985: 348-367.
13. Hopewell PC. Overview of clinical tuberculosis. In: Bloom BR, ed. Tuberculosis. Washington: ASM Press, 1994: 25-46.
14. Daniel TD. Tuberculosis. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 3rd edn. New York: McGraw-Hill 1994: 710-718.
15. Lucas SB. Histopathology of leprosy and tuberculosis: an overview. British Medical Bulletin, 1988; 44: 584-599.
16. Cocito C, Gilot P, Coene M, De Kesel M, Poupart P, Vannuffel P. Paratuberculosis. Clinical Microbiology Review, 1994; 7: 328-345.
17. Collins FM, Mackaness GB. The relationship of delayed hypersensitiviry to acquired antituberculous immunity. I. Tuberculin sensitivity and resistance to reinfection in BCG-vaccinated mice. Cell Immunology, 1970; 1: 253-265.
18. Lefford MJ. Transfer of adoptive immunity to tuberculosis in mice. Infectious Immunology, 1975; 11: 1176-1181.
19. Collins FM. Immunology of tuberculosis. American Review of Respiratory Diseases, 1982; 125 (suppl.): 42-49.
20. Collins FM. Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clinical Microbiology Review, 1989; 2: 360-377.
21. Crowle AJ, May M. Preliminary demonstration of human tuberculo-immunity in vitro. Infection and Immunity, 1981; 31: 453-464.
22. Rook GAW, Steele J, Ainsworth M, Champion BR. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology, 1986; 59: 333-338.
23. Beschin A, Brijs L, De Baetselier P, Cocito C. Mycobacterial proliferation in macrophages is prevented by incubation with lymphocytes activated in vitro with a mycobacterial antigen complex. European Journal of Immunology, 1991; 21: 793-797.
24. Hernandez-Pando R, Rook GAW. The role of TNF-α in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology, 1994; 82: 591-595.
25. Surcel HM, Troye-Blomberg M, Paulie S, Andersson G, Moreno C, PasVol. G, Ivanyi J. Th1/Th2 profiles in tuberculosis based on proliferation and cytokine response of peripheral blood lymphocytes to mycobacterial antigens. Immunology, 1994; 81: 171-176.
26. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology, 1994; 191: 564-568.
27. Rook GAW, Hernandez-Pando R. The pathogenesis of tuberculosis. Annual Review of Microbiology, 1996; 50: 259-284.
28. Barksdale L, Kim KS. Mycobacterium. Bacteriological Review, 1977; 41: 217-372.
29. Daniel TM, Janicki BW. Mycobacterial antigens: a review of their isolation, chemistry, and immunological properties. Microbiology Review, 1978; 42: 84-113.
30. Lederer E, Adam A, Ciorbaru A, Petit JF, Wietzerbin J. Cell wall of mycobacteria and related organisms: chemistry and immunostimulant properties. Molecular and Cellular Biochemistry, 1975; 7: 87-104.
31. McNeil WR, Brennan PJ. Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Research in Microbiology, 1991; 142: 451-463.
32. Young DB, Kauffmann SHE, Hermans PWM, Thole JER. Mycobacterial protein antigens: a compilation. Molecular Microbiology, 1992; 6: 133-145.
33. Closs O, Harboe M, Axelsen NH, Burch-Christensen K, Magnusson M. The antigens of Mycobacterium bovis, strain BCG, studied by cross immunoelectrophoresis: a reference system. Scandinavian Journal of Immunology, 1980; 12: 249-263.
34. Cocito C, Vanlinden F. Preparation and properties of antigen A60 from Mycobacterium bovis BCG. Clinical and Experimental Immunology, 1986; 66: 262-272.
35. Fabre I, L'Homme L, Bruneteau M, Michel G, Cocito C. Chemical composition of antigen A60 from Mycobacterium bovis BCG. Scandinavian Journal of Immunology, 1986; 24: 591-602.
36. Cocito C, Vanlinden F. Composition and immunoreactivicy of the A60 complex and other cell wall fractions from Mycobacterium bovis BCG. Scandinavian Journal of Immunology, 1995; 41: 179-87.
37. Coetsier C, Baelden MC, Coene M, Cocito C. Immunological analysis of the components of the antigen complex A60 of Mycobacterium bovis BCG. Clinical Diagnostic Laboratory Immunology, 1994; 1: 139-144.
38. Hastings RC, Gillis TP, Krahebuhk JL, Franzblau SG. Leprosy. Clinical Microbiology Review, 1988; 1: 330-348.
39. Carlucci S, Beschin A, Tuosto L et al. Mycobacterial antigen complex A60-specific T-cell repertoire during the course of pulmonary tuberculosis. Injection and Immunity, 1993; 61: 439-447.
40. Zou YL, Zhang JD, Chen MH, Shi GQ, Prignot J, Cocito C. Serological analysis of pulmonary and extrapulmonary tuberculosis with enzyme-linked immunosorbent assays for anti-A60 immunoglobulins. Clinical Infectious Diseases, 1994; 19: 1084-1091.
41. Gilot P, De Kesel M, Coene M, Cocito C. Induction of cellular immune reactions by A36, and antigen complex of Mycobacterium paratuberculosis: comparison of A36 and Johnin components. Scandinavian Journal of Immunology, 1992; 36: 811-821.
42. Cocito C. Properties of the mycobacterial antigen complex A60 and its applications to diagnosis and prognosis of tuberculosis. Chest, 1991; 100: 1687-1693.
43. Hubbard RD, Flory CM, Collins IM, Cocito C. Immunization of mice with antigen A60 from M. bovis BCG. Clinical and Experimental Immunology, 1992; 88: 129-131.
44. Douvas GS, Looker DL, Vatter AE, Crowle AJ. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infection and Immunity, 1985; 50: 1-8.
45. Rook GAW, Steele J, Fraher L et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology, 1986; 57: 159-163.
46. Flesch I, Kaufmann SHE. Mycobacterial growth inhibition by interferon-gamma activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. Journal of Immunology, 1987; 138: 4408-4413.
47. Jensen WA, Rose RM, Wasserman AS, Kalb TH, Anton K, Remold HG. In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma-interferon. Journal of Infectious Diseases, 1987; 155: 574-577.
48. Flesch IEA, Kaufmann SHE. Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon activated bone marrow macrophages. Infection and Immunity, 1988; 56: 1404-1409.
49. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, Nathan CF. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon gamma. Journal of Immunology, 1987; 138: 2290-2297.
50. Belosevic M, Nacy CA. Gamma-interferon and other lymphokines cooperate in induction of resistance to Leishmania major infection by macrophages. FASEB Journal, 1987; 46: 4147.
51. Green SJ, Meltzer MS, Hibbs JB, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. Journal of Immunology, 1990; 144: 278-283.
52. Allen C, Hogg N. Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology, 1985; 55: 289-299.
53. Wilson KM, Siegal G, Lord EM. Tumour necrosis factor-mediated cytotoxicity by tumour-associated macrophages. Cell Immunology, 1989; 123: 158-165.
54. Haberts JMW, Tank B, van Joost TL. Characterization of mononuclear infiltrate in Bowen's disease (squamous cell carcinoma in situ). Evidence for a T cell-mediated antitumour immune response. Virchow's Archives A: Pathology and Anatomy, 1989; 415: 125-130.
55. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastases Review, 1989; 8: 319-351.
56. Norazmi MN, Hohman AW, Skinner JM, Jarvis LR, Bradley J. Density and phenotype of tumour-associated mononuclear cells in colonic carcinomas determined by computer-assisted video image analysis. Immunology, 1990; 69: 282-286.
57. Maes H. Prevention of cancer development by the antigen 60 mycobacterial complex and of cancer-promoted inhibition of immune reactions. Brussels: Doctorate thesis, Université Catholique de Louvain 1995: 211-214.
58. Maes H, Taper H, Cocito C. Alteration of the immune response during cancer development and prevention by administration of a mycobacterial antigen. Scandinavian Journal of Immunology 1995: , 41: 53-64.
59. Maes H, Taper H, Cocito C. Comparison between BCG and the A60 mycobacterial complex as cancer preventive immunotherapies. Journal of Cancer Research and Clinical Oncology, 1996; 122: 296-300.
60. Bloemena E, Gall H, Ransom JH et al. Delayed-type hypersensitivity reactions to rumour-associated antigens in colon carcinoma patients immunized with an autologous tumour cell/Bacillus Calmette-Guérin vaccine. Cancer Research, 1993; 53: 456-459.
61. Vaage J, Pepin G. Morphological observations during developing concomitant immunity against a C3H He mammary tumour. Cancer Research, 1985; 45: 659-666.
62. De Kesel M, Gilot P, Coene M, Cocito C. Composition and immunological properties of the protein fraction of A36, a major antigen complex of Mycobacterium paratuberculosis. Scandinavian Journal of Immunology, 1992; 36: 201-212.
63. Miescher S, Whiteside TL, Carrel S, Von Fliedner V. Functional properties of tumour-infiltrating and blood lymphocytes in patients with solid tumours: effects of tumour cells and their supernatants on proliferative responses of lymphocytes. Journal of Immunology, 1986; 136: 1899-1907.
64. Belledegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumour-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumour activity. Cancer Research, 1988; 48: 206-214.
65. Sawamura Y, Hosokawa M, Kupper MC et al. Antitumour activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Research, 1989; 49: 1843-1849.
66. Topalian SL, Solomon D, Rosenberg SA. Tumour-specific cytolysis by lymphocytes infiltrating human melanomas. Journal of Immunology, 1989; 142: 3714-3725.
67. Kedar E, Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Advances in Cancer Research, 1992; 59: 245-322.
68. Barth RJ, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumour-associated antigens identified by tumour infiltrating lymphocytes. Journal of Immunology, 1990; 144: 1531-1537.
69. Rubbert A, Manger B, Lang N, Kaldenand GR, Platzer E. Functional characterization of tumour-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. International Journal of Cancer, 1991; 49: 25-31.
70. Reinhold U, Abken H, Kukel S, Goeden B, Uerlich M, Neumann U, Kreysel HW. Tumour-infiltrating lymphocytes isolated from a Ki-1-positive large cell lymphoma of the skin. Phenotypic characterization and analysis of cytokine secretion. Cancer, 1991; 68: 2155-2160.
71. Maes H, Cocito C. Synthesis of cytokines during tumour development in mice immunized with the mycobacterial antigen complex A60. Scandinavian Journal of Immunology, 1996; 44: 369-374.
72. Peck R, Brockhaus M, Frey JR. Cell surface tumour necrosis factor (TNF) accounts for monocyte and lymphocyte-mediated killing of TNF-resistant target cells. Cellular Immunology, 1989; 122: 1-10.
73. + tumour-infiltrating lymphocytes. Journal of Experimental Medicine, 1991; 173: 647-58.
74. Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH, Varesio L. Tumour necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced murine macrophage tumouricidal activity. Journal of Immunology, 1992; : 3290-6.
75. Celada A, Gray PW, Rinderknecht T, Schreiber RD. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. Journal of Experimental Medicine, 1984; 160: 55-74.
76. Adams DO, Hamilton TA. Molecular transductional mechanisms by which IFN-γ and other signals regulate macrophage development. Immunological Reviews, 1987; 97: 5-27.
77. Narumi S, Finke JH, Hamilton TA. Interferon-γ and interleukin-2 synergize to induce selective monokine expression in murine peritoneal macrophages. Journal of Biological Chemistry, 1990; 265: 7036-7041.
78. Miescher S, Whiteside TL, De Tribolet N, Von Fliedner V. In situ characterization, clonogenic potential, and antitumour cytolytic activity of T lymphocytes infiltrating human brain cancer cells. Journal of Neurosurgery, 1988; 68: 438-448.
79. Maes H, Cocito C. Cancer prevention by adoptive transfer of antigen 60-activated immunocompetent cells. Scandinavian Journal of Immunology, 1996; 43: 283-288.
80. Maes H, Cocito C. In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions. Journal of Cancer Research and Clinical Oncology, 1996; 122: 727-734.
81. Stueh DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumour target cells. Journal of Experimental Medicine, 1989; 169: 1543-1555.
82. Keller R, Geiges M, Keist R. L-Arginine-dependent reactive nitrogen intermediates as mediators of tumour cell killing by activated macrophages. Cancer Research, 1990; 50: 1421-1425.
83. Higuchi M, Higachi N, Taki H, Osawa T. Cytolytic mechanisms of activated macrophages: Tumour necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. Journal of Immunology, 1990; 144: 1425-1431.
84. Nedwin GE, Sverdersky LP, Bringman TS, Palladino MA, Goeddel DV. Effect of interleukin-2, interferon-γ, and mitogens on the production of tumour necrosis factors a and β. Journal of Immunology, 1985; 135: 2492-2497.
85. Nathan CF, Brukner L, Kaplan G, Unkeless JC, Cohn ZA. Role of activated macrophages in antibody-dependent lysis of tumour cells. Journal of Experimental Medicine, 1980; 152: 183-197.
86. Nathan CF, Cohn ZA. Role of oxygen-dependent mechanisms in antibody-induced lysis of tumour cells by activated macrophages. Journal of Experimental Medicine, 1980; 152: 198-208.
87. Nathan CF. Secretory products of macrophages. Journal of Clinical Investigation, 1987; 79: 319-326.
88. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-γ. Journal of Immunology, 1987; 139: 518-525.
89. McDonough KA, Kress Y, Bloom BR. Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infectious Immunology, 1993; 61: 2763-2773.
90. Mc Michael A. Cytotoxic T lymphocytes: specific surveillance and escape. Advances in Cancer Research, 1992; 59: 227-244.
91. Feinman R, Heriksen-De Stefano D, Tsujimoto M, Vilcek J. Tumour necrosis factor is an important mediator of tumour cell killing by human monocytes. Journal of Immunology, 1987; 138: 635-640.
92. Adams DO, Hamilton TA. Molecular basis of macrophage activation: diversity and its origin. In: Lewis CE, McGee JOD, eds. The Natural Immune System: The Macrophage. Oxford: IRL Press 1992: 75-114.
93. Hasday JD, Shah EM, Lieberman AP. Macrophage tumour necrosis factor-α release is induced by contact with some tumours. Journal of Immunology, 1990; 145: 371-379.
94. Janicke R, Mannel DN. Distinct tumour cell membrane constituents activate human monocytes for tumour necrosis factor synthesis. Journal of Immunology, 1990; 144: 1144-1150.
95. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science, 1986; 233: 1318-1321.
96. Greenberg PD. Adoptive T cell therapy of tumours: mechanisms operative in the recognition and elimination of tumour cells. Advances in Immunology, 1991; 49: 281-355.
97. Melief CJM. Tumour eradication by adoptive transfer of cytotoxic T lymphocytes. Advances in Cancer Research, 1992; 58: 143-175.
98. Borden EC, Sondal PM. Lymphokines and cytokines as cancer treatment. Cancer, 1990; 65: 800-814.